Virtual Library
Start Your Search
T. Kato
Author of
-
+
P3.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 235)
- Event: WCLC 2015
- Type: Poster
- Track: Biology, Pathology, and Molecular Testing
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.04-066 - Overexpression of KIF23 Predicts Clinical Outcome in Primary Lung Cancer Patients (ID 850)
09:30 - 09:30 | Author(s): T. Kato
- Abstract
Background:
Lung cancer is the leading cause of cancer-related mortality worldwide. To improve the survival rate, it is important to examine or analyze metastatic lymph node samples taken from advanced lung cancer patients, especially using minimally invasive techniques like endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA). We have been attempting to isolate potential molecular targets for lung cancer by analyzing expression profiles of our microarray and various types of database. Throughout these screenings, we identified kinesin family member 23 (KIF23) as a promising molecular target gene for the treatment of lung cancer. High-level expression of KIF23, a member of microtubule-dependent molecular motors that transport organelles within cells and move chromosomes during cell division, has been observed in a variety of human malignancies. The aims of the present study were to observe the expression of KIF23 in human lung cancer, examine the role of KIF23 in lung cancer cell growth and/or survival by small interfering RNA experiments, and explore its clinicopathologic significance and evaluate KIF23 expression as a prognostic marker.
Methods:
Quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis was performed to detect the expression of KIF23 mRNA using metastatic lymph nodes from patients with advanced lung cancer obtained by EBUS-TBNA and normal human organs. A role of KIF23 in cancer cell growth and/or survival was examined by small interfering RNA experiments. A total of 341 lung cancers were analyzed immunohistochemically on tissue microarrays to examine the expression of KIF23 protein in archival lung cancer samples and its clinicopathologic significance.
Results:
KIF23 transcript was extremely higher in the great majority of metastatic lymph nodes from advanced lung cancers with higher frequency compared with the average expression of normal lung tissues as determined by quantitative RT-PCR. KIF23 was more highly expressed only in the testis and the thymus compared to other human organs. Inhibiting KIF23 expression effectively suppressed non-small cell lung cancer (NSCLC) cell growth, and KIF23 siRNA-treated lung cancer cells more frequently exhibited large cell bodies with two or more nuclei. High-level KIF23 expression was observed in 67.7% of the 341 cases, and this only correlated with pathological T classification (P=0.0269). Lung adenocarcinoma patients with tumors displaying a high-level of KIF23 expression was also identified as an independent prognostic factor by multivariate analysis (P=0.0042). Figure 1
Conclusion:
KIF23 not only provides additional prognostic information for surgical treatment of lung cancer, but may also be a novel therapeutic target for these patients.
